ZNF697 Inhibitors
ZNF697 inhibitors form a diverse group of compounds that each take a unique approach to downregulate the functional activity of the ZNF697 protein. Histone deacetylase inhibitors like Trichostatin A, and DNA methyltransferase inhibitors such as 5-Azacytidine, target epigenetic mechanisms. They modify chromatin architecture and DNA methylation patterns, respectively, which can lead to reduced ZNF697 binding to DNA and a consequent decrease in its regulatory influence on gene expression. Similarly, proteasome inhibitors like MG-132 and Bortezomib can indirectly diminish ZNF697 function by stabilizing proteins that regulate its activity, or by overwhelming the protein degradation pathways, including those that might manage ZNF697 levels. This modulation of proteostasis is critical for maintaining the balance of intracellular protein levels and can lead to decreased ZNF697 activity when perturbed.
Compounds suchas PD 98059, LY 294002, and Rapamycin act on specific signaling pathways and protein synthesis processes to indirectly reduce ZNF697 activity. PD 98059 suppresses the MAPK/ERK pathway, which may downregulate transcription factors controlling ZNF697 expression, leading to less ZNF697 function. LY 294002 inhibits the PI3K/AKT signaling cascade, potentially affecting the stability and activity of ZNF697 by targeting proteins downstream in this pathway. Rapamycin, an mTOR pathway inhibitor, can lower the production of proteins, including ZNF697, thus impeding its regulatory role. Other inhibitors, such as SB 431542, Triptolide, Chetomin, JQ1, and Alisertib, leverage diverse mechanisms involving TGF-β receptor signaling, transcriptional repression, disruption of HIF-1 function, interference with BET bromodomains, and alteration of cell cycle-related protein phosphorylation to decrease the expression or activity of ZNF697. These inhibitors collectively employ a multifaceted approach to reducing ZNF697's influence on gene regulation, thereby achieving functional inhibition through interference at various biological levels.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that can lead to chromatin remodeling, affecting the expression of various genes including ZNF697. This alteration in the chromatin state can diminish ZNF697's ability to bind DNA and regulate gene expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA, potentially leading to the reactivation of genes that suppress ZNF697 expression, thereby leading to a decrease in ZNF697 protein levels and its functional activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, which could include transcription factors or other proteins that negatively regulate ZNF697, resulting in decreased ZNF697 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway. By inhibiting this pathway, it may downregulate transcription factors that enhance ZNF697 expression, thereby diminishing ZNF697's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that may reduce the activity of downstream signaling proteins including AKT, which could be involved in the stabilization and activity of ZNF697, ultimately leading to diminished ZNF697 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can downregulate protein synthesis and potentially decrease the levels of ZNF697 as well as its target proteins, thus impairing ZNF697's regulatory functions. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB 431542 is an inhibitor of the TGF-β receptor which may lead to altered SMAD signaling. Downstream effects of this inhibition can result in the reduced expression of ZNF697, as its expression may be regulated by TGF-β signaling. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is a compound known to inhibit transcription by RNA polymerase II. This can diminish the expression of ZNF697 and its target genes, thereby decreasing ZNF697's regulatory effects on gene expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to the accumulation of misfolded proteins, indirectly reducing the stability and function of ZNF697 by overwhelming the protein degradation machinery that may otherwise regulate ZNF697 levels. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the function of hypoxia-inducible factor 1 (HIF-1), which may be involved in the transcriptional regulation of ZNF697. By diminishing HIF-1 activity, Chetomin can decrease ZNF697's expression and its downstream effects on gene regulation. | ||||||